TransCode Therapeutics, Inc. (RNAZ) Q1 2026 Annual Earnings
RNAZ·Reported May 15, 2026·Before market open
Diluted EPS came in at $-21.28 (-26.6% YoY).
Diluted EPS
$-21.28
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about TransCode Therapeutics, Inc.'s Q1 2026 earnings report.
TransCode Therapeutics, Inc. (RNAZ) reported Q1 2026 earnings on May 15, 2026 before market open.
TransCode Therapeutics, Inc. reported diluted EPS of $-21.28 for Q1 2026.
Compared to the same quarter a year prior, diluted EPS declined 26.6% from $-16.81.
You can read the 10-K periodic report (0001104659-26-043810) directly on SEC EDGAR. The filing index links above go to sec.gov.